Insulinsyringe (U100-type, 0.5ml with 0.30 x 8mm needle)Also known as: Insuline spuit 0,5ml, U100 insuline syringe, Fine needle insulin syringe

Mechanism of Action

Not applicable. This is an injection device designed for precise subcutaneous delivery of peptides and other compounds, enabling accurate dosing by allowing administration of measured liquid volumes.

Reported Research Benefits

Used primarily for the subcutaneous injection of peptides such as BPC-157, TB-500, and Ipamorelin in research or therapeutic contexts. Designed for precise, sterile, single-use administration of liquid compounds.

Dosing Protocol & Reconstitution

Typically used to administer doses as prescribed by peptide research protocols. A single pack of 10 syringes is generally sufficient for 5-10 days of peptide injections depending on dosing frequency and volume.

Research Notes

The fine needle size (0.30 mm x 8 mm) minimizes tissue damage and discomfort during subcutaneous injections. The 0.5 ml U100 scale allows for precise volume measurement of injected peptides or compounds.

Research Summary

Insulinsyringe (U100-type, 0.5ml with 0.30 x 8mm needle) is a medical device specifically designed for the precise subcutaneous administration of insulin and other injectable peptides. Clinical studies have demonstrated that using appropriately sized needles improves patient comfort and dosing accuracy, reducing the risk of hypoglycemia related to insulin administration. Evidence primarily comes from clinical practice observations and device evaluation studies rather than randomized controlled trials, highlighting effective delivery and improved patient adherence. Limitations include variability in patient technique and needle length optimization depending on individual subcutaneous fat thickness.

Side Effects & Safety

As a medical injection device rather than a bioactive peptide, insulinsyringes themselves do not have pharmacological side effects. However, improper use can lead to injection site complications such as pain, bruising, lipodystrophy, or infection. The needle size (0.30 x 8mm) is selected to minimize tissue trauma, but repeated injections may still cause localized skin reactions. There are no direct drug interactions, but care must be taken to use sterile technique and to avoid reuse to prevent contamination. WADA status is not applicable, as this is a delivery device and not a controlled substance or doping agent.

Stability & Storage

Refer to research notes

Molecular Data

Primary literature: https://pubmed.ncbi.nlm.nih.gov/?term=Insulinsyringe+U100-type+0.5ml+needle